What is Stickiness Phenomena? What stickiness phenomena is, how it originates and how it can impacts pharmaceuticals pricing and procurement? Is therapeutic adherence always standing on sound grounds? Concerning biological and biosimilar products in Europe, many of the components that define the stickiness phenomena, although explainable, seem to be arguably rational. In many European countries switching a patient fr
April 1, 2019 amendments to Regulation 10 concerning pharmaceutical product reimbursement were introduced. Can the new rules limit competition in the sector? New rules effective April 1, 2019, allow NHIF to charge pharmaceutical companies if their sales exceed sales (value) from previous periods. The sales numbers will be now monitored every quarter. As introduced, the current rules are expected to bear future revisi
On February 26, 2019, the Committee on Legal Affairs of the European Parliament approved the draft text of the regulation on supplementary protection certificate SPC waiver. Earlier this year, the Legal Committee of the European Parliament (JURI) has voted in favor of the SPC manufacturing waiver. Read the full article on LinkedIn. With the introduction of SPC waiver for export and stockpiling, generic and biosimilar
Expected Patent Expiry of Biological Products in Europe 2018 - 2027 and CAR-T entrants in 2018. Kinase inhibitor products patents expiry in Europe. Not exhaustive list of products. Brand names included.
National identity of a company: the perception of national belonging that we perceive of a company from it's name. For example: the mental impression from the name "British Airways" is that it is a British company.